Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials
- PMID: 31303960
- PMCID: PMC6611508
- DOI: 10.18632/oncotarget.26981
Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials
Abstract
Simon's two-stage design and the admissible two-stage design have been commonly used in practice for single-arm phase II clinical trials when the primary endpoint is binary. The ethical benefit of the two-stage design over the single-stage design is attained by the early termination of the trial when the treatment seems to be inactive. While Simon's optimal design is the two-stage design that minimizes the expected number of subjects under the null hypothesis, the probability of falsely declaring futility after the first stage frequently seems undesirably high. In Simon's minimax design, however, it is often the case that a high proportion of the total planned subjects are evaluated in the first stage, and thus the ethical benefit may not be achieved. In this paper, we propose modified minimax and optimal two-stage designs which guarantee not only type I and II error rates but also reasonable sample size proportions in the first stage, while maintaining the probability of falsely declaring futility under a pre-selected level. The characteristics of the modified two-stage design will be compared with those of Simon's and the admissible two-stage design. The modified minimax design yields a design that requires modest increase in 29% of cases, while the modified optimal design saves 1 to 13 subjects in 81% of cases for β = 0.2. The modified design approach provides investigators with an alternative when the sample sizes of Simon's designs are severely unbalanced or the Type II error is unacceptably high after the first stage.
Keywords: Simon’s two-stage design; admissible two-stage design; binary endpoint; modified two-stage design; single-arm phase ii clinical trials.
Conflict of interest statement
CONFLICTS OF INTEREST The authors report no relevant conflicts of interest.
Figures


Similar articles
-
Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.BMC Med Res Methodol. 2020 May 20;20(1):126. doi: 10.1186/s12874-020-01017-8. BMC Med Res Methodol. 2020. PMID: 32434577 Free PMC article.
-
Optimal futility stopping boundaries for binary endpoints.BMC Med Res Methodol. 2024 Mar 28;24(1):80. doi: 10.1186/s12874-024-02190-w. BMC Med Res Methodol. 2024. PMID: 38539108 Free PMC article.
-
Minimax and admissible adaptive two-stage designs in phase II clinical trials.BMC Med Res Methodol. 2016 Aug 2;16:90. doi: 10.1186/s12874-016-0194-3. BMC Med Res Methodol. 2016. PMID: 27485595 Free PMC article.
-
Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.BMC Med Res Methodol. 2022 Dec 22;22(1):327. doi: 10.1186/s12874-022-01810-7. BMC Med Res Methodol. 2022. PMID: 36550391 Free PMC article.
-
Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.Contemp Clin Trials. 2015 May;42:9-17. doi: 10.1016/j.cct.2015.02.007. Epub 2015 Mar 3. Contemp Clin Trials. 2015. PMID: 25749311 Free PMC article. Review.
Cited by
-
Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.BMC Med Res Methodol. 2020 May 20;20(1):126. doi: 10.1186/s12874-020-01017-8. BMC Med Res Methodol. 2020. PMID: 32434577 Free PMC article.
-
Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.Contemp Clin Trials. 2022 Sep;120:106849. doi: 10.1016/j.cct.2022.106849. Epub 2022 Jul 19. Contemp Clin Trials. 2022. PMID: 35868503 Free PMC article. Clinical Trial.
-
Promising zone two-stage design for a single-arm study with binary outcome.Stat Methods Med Res. 2023 Jun;32(6):1159-1168. doi: 10.1177/09622802231164737. Epub 2023 Mar 30. Stat Methods Med Res. 2023. PMID: 36998163 Free PMC article.
-
Optimal two-stage design of single arm Phase II clinical trials based on median event time test.PLoS One. 2021 Feb 8;16(2):e0246448. doi: 10.1371/journal.pone.0246448. eCollection 2021. PLoS One. 2021. PMID: 33556130 Free PMC article.
-
Optimal futility stopping boundaries for binary endpoints.BMC Med Res Methodol. 2024 Mar 28;24(1):80. doi: 10.1186/s12874-024-02190-w. BMC Med Res Methodol. 2024. PMID: 38539108 Free PMC article.
References
-
- Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010; 16:1764–69. 10.1158/1078-0432.CCR-09-3287. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources